AJCC第7版实施前后早期黑色素瘤淋巴结阳性率与活检率变化
结果显示2010年后淋巴结手术比例下降3.8%,淋巴结阳性率下降1.0%,而接受评估的T1b期黑色素瘤比例从48.8%升至62.2%。
要点
- AJCC第7版实施后T1期黑色素瘤淋巴结活检率下降,但淋巴结阳性率无临床相关变化。
- 接受淋巴结评估的T1b期黑色素瘤比例增加,从48.8%升至62.2%。
- T1b期黑色素瘤的评估标准从Clark分级和溃疡为主转向以有丝分裂率升高为主。
核心结论
- AJCC第7版实施后,接受淋巴结活检的T1期黑色素瘤数量总体减少,哨兵淋巴结阳性率无临床相关变化,同时接受淋巴结评估的T1b期黑色素瘤数量增加。
主要发现
- 接受评估的T1b期黑色素瘤比例从48.8%升至62.2%(P < .001)。
关键数值与推荐
- 2004至2009年接受淋巴结评估的T1b期黑色素瘤中,74.0%为Clark IV级或V级,9.5%伴溃疡。
- 2010至2013年接受淋巴结评估的T1b期黑色素瘤中,82.6%仅有有丝分裂率升高,3.7%伴溃疡,13.7%同时有溃疡和有丝分裂率升高。
临床怎么用
- 临床可参考AJCC第7版实施后T1期黑色素瘤淋巴结活检率下降而阳性率无临床相关变化的趋势,个体化评估T1b期患者淋巴结活检指征。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: There has been a continued increase in the incidence of newly diagnosed melanomas, most of which are T1 melanomas. The associations between changes in tumor staging, implemented with the 7th edition of the AJCC Cancer Staging Manual (AJCC 7), and sentinel lymph node biopsy rates and nodal positivity rates remain to be seen. OBJECTIVE: To evaluate the change that the implementation of the AJCC 7 had on staging criteria and the distribution of thin melanomas requiring nodal surgery and nodal positivity rates. DESIGN, SETTING, AND PARTICIPANTS: Retrospective cross-sectional study from 2004 through 2013 of all adults (≥18 years) diagnosed with a T1 (Breslow depth ≤1.0 mm) melanoma using The National Cancer Database that captures 70% of all newly diagnosed cancers from accredited Commission on Cancer organizations, including both academic and community settings. Data were analyzed in May 2017. EXPOSURES: Patients were grouped together based on year of diagnosis, before and after 2009. MAIN OUTCOMES AND MEASURES: To determine the sentinel lymph node biopsy rate before and after the implementation of the AJCC 7. RESULTS: A total of 141 280 patients met inclusion criteria. Of 86 846 patients diagnosed from 2004 through 2009, 53.7% (49 644) were male and had a mean (SD) age of 57.7 (16.4) years. Of 54 434 patients diagnosed from 2010 through 2013, 54.3% (31 086) were male and had a mean (SD) age of 59.5 (15.9) years. After 2010, there was a 3.8% decrease in the number of nodal surgeries performed (32 485 of 86 846 patients [37.6%] vs 18 379 of 54 434 patients [33.8%]; P < .001). The nodal positivity rate decreased 1.0% from (9.8% [3166 of 86 846] to 8.8% [1618 of 54 434]) (P < .001). An increase in the proportion of T1b melanomas being evaluated, from 48.8% to 62.2%, was seen (P < .001). Of T1b melanomas that underwent nodal evaluation from 2004 through 2009, 74.0% had Clark level IV (invasion of the reticular dermis) or Clark level V (invasion of the deep, subcutaneous tissue) and 9.5% were ulcerated. From 2010 through 2013, of the T1b melanomas undergoing nodal evaluation, 82.6% had an elevated mitotic rate only, 3.7% were ulcerated, and 13.7% had both ulceration and an elevated mitotic rate. CONCLUSIONS AND RELEVANCE: It appears that after the institution of AJCC 7, there was an overall decrease in the number of T1 melanomas undergoing nodal biopsy without a clinically relevant change in sentinel lymph node positivity, with an increase in the number of T1b melanomas undergoing nodal evaluation.
引用
- Isom C, Wheless L, Hooks MA, et al. Early Melanoma Nodal Positivity and Biopsy Rates Before and After Implementation of the 7th Edition of the AJCC Cancer Staging Manual. JAMA Dermatol. 2019. PMID: 30840034. doi:10.1001/jamadermatol.2018.5902
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。